← Eichor
Study identifier: NCT06453733 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Crainio Non-invasive ICP Monitor for TBI

Condition: Traumatic Brain Injury  ·  Sponsor: Crainio Ltda

PhaseNA
Planned participants54
Who can joinAll sexes, 16 Years to 99 Years
Healthy volunteersNo

About this study

The clinical investigation aims to advance the Crainio device, designed for non-invasive intracranial pressure (ICP) monitoring. This feasibility study involves 54 participants over a 12-month period and seeks to collect cerebral photoplethysmogram signals alongside concurrent invasive ICP measurements in patients with traumatic brain injury. The primary objective is to establish the diagnostic accuracy of the Crainio device, aiming for at least 90% sensitivity and specificity in detecting raised ICP (above 20 mmHg). Secondary objectives include evaluating patient-related factors such as skin tone, skull thickness, and skull density, as well as the tolerability and acceptance of the device by both patients and healthcare professionals.

This description comes directly from the study's public registry record.

Talk to the study team

Jeremy Holland, Dr  ·  0779 626 5994  ·  Jeremy.Holland@crainio.com

Always discuss trial participation with your own doctor first.

Locations (1)

Royal London HospitalLondon, England, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06453733